NitroSynapsin NMDAR Inhibition for Restoring E/I Balance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurological conditions such as MEF2C haploinsufficiency syndrome (MCHS), autism spectrum disorders (ASD), intellectual and developmental disabilities (IDD), epilepsy, and Rett syndrome are inadequate, particularly in addressing E/I imbalance and associated behavioral and synaptic abnormalities.

Innovation Solution

The use of NitroSynapsin, an inhibitor of N-methyl-D-aspartate type of glutamate receptor (NMDAR), to treat juvenile-onset neurological conditions by restoring synaptic function and balancing excitatory and inhibitory neurotransmission.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments are used for neurological conditions, then existing therapeutic approaches are maintained, but E/I imbalance and associated behavioral and synaptic abnormalities are not adequately addressed

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidability to address E/I imbalance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent employs NMDAR inhibitors that selectively modulate glutamate receptor activity parameters to restore E/I balance. By changing the pharmacological parameters of glutamate reception, the treatment addresses both synaptic abnormalities and behavioral deficits associated with MEF2C haploinsufficiency and other neurological conditions.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If NMDAR inhibitors are used to treat neurological conditions, then synaptic function is restored and E/I balance is improved, but potential off-target effects and toxicity may occur

Engineering Contradiction:

Improvesynaptic function restorationVSAvoidoff-target effects and toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent utilizes NMDAR inhibitors with selective action on specific neuronal populations and synapses affected by MEF2C haploinsufficiency. This localized pharmacological action restores synaptic function in affected circuits while minimizing off-target effects on healthy brain regions.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The treatment employs partial NMDAR inhibition rather than complete blockade, achieving sufficient E/I balance restoration without excessive suppression of glutamatergic transmission. This partial action approach maintains adequate excitatory signaling while correcting the imbalance.

Inventive Principle:

Principle #16Partial or excessive action

3Reliability

If MEF2C haploinsufficiency is present, then neuronal differentiation and synaptic formation are impaired, but complete recovery of neuronal function is difficult to achieve

Engineering Contradiction:

Improveneuronal differentiationVSAvoidneuronal function stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies NMDAR inhibition as a preliminary therapeutic intervention that creates favorable conditions for subsequent neuronal recovery. By first correcting the E/I imbalance and reducing excitotoxic stress, the treatment stabilizes the neuronal environment, enabling improved synaptic function and behavioral outcomes.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12576042B2Methods and compositions for treating neurological conditions

Publication Date: 2026.03.17 LIPTON STUART A

AI summary

Disclosed herein are methods for treating juvenile onset neurological conditions, such as autism (ASD), intellectual disability, or epilepsy, with an inhibitor of N-methyl-D-aspartate receptor (NMDAR). The inhibitor may be NitroSynapsin or a derivative thereof.